Rezolute Stock Forum

$Rezolute (RZLT.US)$ 👀  mediocre catalyst

$Rezolute (RZLT.US)$
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
Rezolute, Inc. (Nasdaq: RZLT) announced that the FDA has lifted partial clinical holds on RZ358 (ersodetug), their potential treatment for hypoglycemia caused by congenital hyperinsulinism (HI). This allows the company to include U.S. participants in their ongoing global Phase 3 sunRIZE study. Rezolute plans to begin U.S. enrollm...

$Rezolute (RZLT.US)$ Reuters· 1 min ago
FDA Lifts Partial Clinical Holds on Rz358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

$Apple (AAPL.US)$ Update
$Rezolute (RZLT.US)$ Reuters· 6 mins ago
Rezolute Announces FDA Clearance of Ind Application for Phase 3 Registrational Study of Rz358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Update
$Rezolute (RZLT.US)$ Reuters· 6 mins ago
Rezolute Announces FDA Clearance of Ind Application for Phase 3 Registrational Study of Rz358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

$Rezolute (RZLT.US)$ Reuters· 6 mins ago
Rezolute Announces FDA Clearance of Ind Application for Phase 3 Registrational Study of Rz358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

$Rezolute (RZLT.US)$
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

$Rezolute (RZLT.US)$ According to ShareIntel, they leverage patented processes and proprietary analytics to support identification of reporting anomalies among market makers, banks, broker-dealers and clearing firms. The ShareIntel DRIL-Down™ platform identifies markers of potential illegal naked short selling. Armed with actionable intelligence, ShareIntel assists public companies in their effort to help enable true price discovery.

Work continues
$Rezolute (RZLT.US)$
     - PB of 2.8
     - No debt, 106m cash
$Data Storage (DTST.US)$
     - Profitable
     - P/B 1.15x
     - P/S .97x
$Broadwind (BWEN.US)$
     - Profitable and Undervalued
Gonna add to DTST more. Holding the others for now.
$Candel Therapeutics (CADL.US)$
- Unprofitable
- Overbought and bear signals
$Innovative Eyewear (LUCY.US)$
- Unprofitable and major cash burn
$XPeng (XPEV.US)$
- Unprofitable
- Bearish trend
Gonna sell those positions.